Public listing of Serendex Pharmaceuticals A/S at Oslo Axess

Serendex is developing a diversified portfolio of new repositioned drugs based on existing well-known drugs for the treatment of life-threatening lung diseases which have a high medical need. All of Serendex’ products have an accelerated development and approval timeline as well as high potential for commercial penetration in the global market.

Quotes, details on the share and the company, notifications and historical prices